These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22683425)

  • 1. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
    Pawlak K; Ulazka B; Mysliwiec M; Pawlak D
    Transl Res; 2012 Nov; 160(5):346-54. PubMed ID: 22683425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
    Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
    Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
    Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
    Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
    Pawlak K; Pawlak D; Myśliwiec M
    Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
    Pawlak K; Mysliwiec M; Pawlak D
    Thromb Res; 2010 Feb; 125(2):e40-5. PubMed ID: 19732942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients.
    Pawlak K; Zolbach K; Borawski J; Mysliwiec M; Kovalchuk O; Chyczewski L; Pawlak D
    Thromb Res; 2008; 123(1):166-70. PubMed ID: 18452978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
    Konukoglu D; Turhan MS; Celik V; Turna H
    Indian J Med Res; 2007 Jun; 125(6):747-51. PubMed ID: 17704550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
    Pawlak K; Mysliwiec M; Pawlak D
    Thromb Res; 2008; 122(3):328-35. PubMed ID: 18048089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood urokinase plasminogen activator system in chronic urticaria.
    Kasperska-Zajac A; Brzoza Z; Rogala B
    Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
    Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
    Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors.
    Braza-Boïls A; Marí-Alexandre J; Gilabert J; Sánchez-Izquierdo D; España F; Estellés A; Gilabert-Estellés J
    Hum Reprod; 2014 May; 29(5):978-88. PubMed ID: 24608518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
    Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
    BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.